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tTranslating whole exome sequencing (WES) for prospective clinical use may impact the care of
cancer patients; however, multiple innovations are necessary for clinical implementation. These
include: (1) rapid and robust WES from formalin-fixed paraffin embedded (FFPE) tumor tissue,
(2) analytical output similar to data from frozen samples, and (3) clinical interpretation of WES
data for prospective use. Here, we describe a prospective clinical WES platform for archival FFPE
tumor samples. The platform employs computational methods for effective clinical analysis and
interpretation of WES data. When applied retrospectively to 511 exomes, the interpretative
framework revealed a “long tail” of somatic alterations in clinically important genes. Prospective
application of this approach identified clinically relevant alterations in 15/16 patients. In one
patient, previously undetected findings guided clinical trial enrollment leading to an objective
clinical response. Overall, this methodology may inform the widespread implementation of
precision cancer medicine.
Introduction
Massively parallel sequencing approaches such as whole exome sequencing (WES) have
elucidated the landscape of genetic alterations in many tumor types and revealed biological
insights relevant to clinical contexts1. The increased practical availability and decreased cost
of tumor genomic profiling has generated opportunities to test the “precision medicine”
hypothesis in clinical oncology2. In principle, knowledge of alterations in the coding regions
of all genes may inform immediate treatment choices and further therapeutic discovery
efforts3.
Most prospective clinical genotyping efforts have utilized “hotspot” genotyping4–6 or
targeted sequencing panels of clinically relevant genes using either fresh frozen or formalin-
fixed, paraffin-embedded (FFPE) tissue7–9. Pilot studies that apply research-grade massively
parallel sequencing technology in focused clinical settings have also been reported7,10–12,
although production-scale efforts have not been demonstrated. Multiple challenges to
widespread clinical WES implementation remain. One challenge involves rapidly generating
high-quality WES data from archival FFPE tumor material13. Another involves clinically
interpreting WES data for prospective use that maximizes clinical and biological
exploration. A third involves developing a system to interrogate plausibly actionable
variants of uncertain significance. Overcoming these challenges should allow rigorous
assessment of the value of WES to guide clinical decision-making and inform selected
experimental follow-up.
Here we describe an approach to generate high-quality WES data from archival tumor
material and validate FFPE WES sequencing data with corresponding frozen WES. We also
present a heuristic algorithm that interprets the resulting data for clinical oncologists, and
establish the clinical applicability of this interpretation algorithm in a retrospective cohort of
511 cases. Prospective application of this platform in patients with a range of tumor types
indicates that this approach enables both biological discovery and clinical trial enrollment.
This approach may therefore facilitate widespread application of WES for precision cancer
medicine studies.
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Whole exome sequencing of FFPE samples
To produce WES data for clinical use, robust sequencing data must frequently be generated
from small quantities of archival FFPE tissue. To test this, DNA was extracted from 99
FFPE samples using the FFPE extraction protocol (Supplementary Table 1, Methods). A
comparison of standard WES metrics14 with 768 non-FFPE samples (394 whole blood, 367
frozen, 7 cell lines) sequenced in parallel demonstrated no significant differences
independent of input DNA quantity (P > 0.05, Mann-Whitney Test; Fig. 1A–C,
Supplementary Table 1). Our lowest successful WES attempts were 13.6ng and 16ng for
non-FFPE and FFPE-derived DNA, respectively.
Moreover, improvements in process design (Methods) combined with the “with-bead”
approach14 yielded a time to exome data delivery of 17.4 ± 2.2 days (median ± s.d; 25th/75th
percentiles 14.3 and 18.6) for FFPE samples received as DNA and 20.1 ± 2.4 days (median
± s.d; 25th/75th percentiles 17.5 and 21.2) days for samples received as FFPE tissue blocks
(Supplementary Table 2). This turn-around time is compatible with several clinical oncology
applications.
We next assessed WES using even smaller amounts of input DNA. Here we achieved > 80%
of targeted nucleotides from the hybrid selection reaction, even when only 1ng input DNA
was used; equivalent results were seen with FFPE and non FFPE-derived DNA. However, to
meet our metrics of ≥ 80% targets ≥ 20x and ≥ 100X mean target coverage, a
disproportionate amount of additional sequencing was required due to an increase in the
fraction of duplicate molecules in the library.
FFPE and Fresh Frozen samples yield comparable WES results
Next, we sought to compare WES data generated from FFPE and frozen material. We
assessed WES data from 11 lung adenocarcinomas for which tumor and adjacent normal
tissue were available from matched FFPE (aged ≤ 5 years, Supplementary Table 3,
Supplementary Figs 1–2) and frozen samples (Fig. 2A). First, we applied our standard
mutation detection pipeline on the tumor-normal pairs (Methods) and considered the
concordance of mutation calls observed in FFPE tumors that were observed in frozen
tumors, and vice versa. We did not expect identical data given tumor heterogeneity15 and
nucleotide transition artifacts induced by FFPE fixation16–18. Moreover, the mean target
coverage achieved for the FFPE tumor and adjacent tissue samples were 1.5–2 times that for
the corresponding FF samples (Supplementary Fig. 3); as a result, we had increased power
to detect mutations in FFPE samples compared to the FF samples19. Therefore, we
considered the subset of observed exonic mutations in FFPE cases where the depth of
coverage afforded sufficient power (> 95%) to detect the mutation in ≥ 2 reads in the
matched frozen case, and vice versa. For sufficiently powered sites, 91.5% (2923/3194, 95%
confidence interval (CI) ± 0.97) of FFPE mutations validated in patient-matched frozen
samples. Similarly, 91.0% (3399/3735, 95% CI ± 0.92) frozen mutations validated in
sufficiently powered FFPE samples (P = 0.47) (Fig. 2A–C, Supplementary Table 4). Since
the mean target coverage in the FFPE cases were higher than their FF counterparts, we then
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coverage of 90X (“downsampling”19) and repeated the cross-validation exercise. In this
scenario, our FFPE to FF and FF to FFPE validation rates for sufficiently powered sites
were 92.6% (2811/3036, 95% CI ± 0.93) and 91.5% (3340/3651, 95% CI ± 0.90),
respectively (Supplementary Fig. 4A–B, Supplementary Table 4).
In both FFPE and FF cases from each patient, mutations were observed where there was
insufficient power to detect that mutation in the validation cohort after downsampling
(Supplementary Fig. 4C, Supplementary Table 4). Demonstrative examples of FFPE
mutations that could not be validated in FF counterparts are provided in Supplementary Fig.
5A–C. Overall, these results suggested that the ability to detect base mutations that were
sufficiently powered was equivalent regardless of whether frozen or FFPE-derived genomic
DNA was used for WES.
We also examined the chromosomal copy number patterns evident in WES data from frozen
and FFPE DNA in these 11 cases. In one demonstrative patient, copy ratios for matching
exons in FFPE and frozen data correlated (R2 = 0.89, p < 0.0001 (Pearson); Fig. 2D–E).
This correlation held across all 11 cases, representing 1338859 exons (R2 = 0.79, p < 0.0001
(Pearson); Fig. 2F). Thus, WES data obtained from FFPE tumor DNA is comparable to FF
WES data, and may equally be used to measure global chromosome copy number
information.
Clinical analysis and interpretation of exome sequencing data
Having demonstrated robust WES using FFPE-derived tumor DNA, we next sought to
integrate this methodology into a broader framework for clinical interpretation of somatic
alterations. We reasoned that a heuristic (rule-based) approach that incorporated prior
clinical and scientific knowledge might offer a useful set of organizing principles. By
utilizing primary literature, manual curation, and expert opinion, we generated a database of
tumor alterations relevant for genomics-driven therapy (TARGET), a database of genes that
may have therapeutic, prognostic, and diagnostic implications for cancer patients (Fig. 3B,
Supplementary Table 5, Methods). We integrated the resulting 121 TARGET genes with
existing open-source resources to create a series of rules that: (i) sort each somatic variant by
clinical and biological relevance; (ii) link TARGET genes with additional biologically
significant pathways and gene sets; and (iii) demote variants of uncertain significance. Thus,
the resulting analytical algorithm used precision heuristics for interpreting the alteration
landscape (PHIAL) (Fig. 3A–D, Methods). Beyond annotating variants, PHIAL applies
rules that rank variants based on clinical and biological relevance to computationally sort a
patient’s somatic variants.
The functionality of PHIAL was assessed using 511 patient cases from six prior WES
studies20–25. Analysis tools (Methods) yielded 258,226 somatic alterations in protein coding
genes, of which 135,903 were non-synonymous. Of these, PHIAL identified 1,842 somatic
alterations in genes linked to clinical actions (TARGET genes) for 80% (408/511) of the
patients (Fig. 3E). Additional descriptive statistics regarding altered genes per patient,
stratified by inclusion in databases explored in PHIAL, is available in Supplementary Table
6. PHIAL identified known and highly recurrent actionable findings across this patient
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tcohort. It also revealed a “long tail” of TARGET gene alterations present in small patient
subsets that did not reach statistical significance in the individual cohort studies but may
have immediate clinical ramifications for individual patients (Fig. 3F). Specifically, 39%
(201/511) of the cases had alterations in at least one TARGET gene that was somatically
altered in less than 2% of the overall cohort. This finding was reminiscent of similar long
tail alteration distributions observed for driver genes in cancer1.
Since a major near-term goal of precision cancer medicine is to use genetic information to
inform clinical trial enrollment, we also systematically queried ClinicalTrials.gov, a
centralized registry of publicly and privately supported clinical studies worldwide, for
oncology clinical trials linked to TARGET genes. The number of clinical trials including a
TARGET gene in the title, the strictest means of identifying clinical trials with a genomic
emphasis, grew steadily between 2005 and 2012 (Fig. 3G).
Prospective WES identifies clinically actionable findings across tumor types
To pilot prospective sequencing and clinical interpretation, we performed WES and PHIAL
on 16 appropriately consented patients with a range of advanced cancers (Fig. 4A). WES
data for 3 of these 16 patients predated the WES protocol described herein, but were
included to assess PHIAL output. WES from all patients in the rapid sequencing protocol
met our quality control parameters irrespective of tissue processing type (Supplementary
Table 7). By completion of the pilot period, sample receipt through data delivery was 16
days.
For these 16 patients, PHIAL revealed 29 unique TARGET genes in the “Investigate
Clinical Relevance” category (median: 2, range: 0–5). Although, by definition, alterations in
TARGET genes may have implications for clinical decision-making, their actual clinical
relevance requires case-by-case evaluation in real time. To facilitate this, every alteration
ranked as “Investigate Clinical Relevance” by PHIAL was manually curated to include up-
to-date knowledge from databases, literature, and computational algorithms. A standardized,
structured annotation was generated for each alteration (Supplementary Note 1), and a level
of evidence was assigned to each potential clinical action based on that alteration. These
levels of evidence (Table 1) include predictive, prognostic, and diagnostic categories, and
encompass validated indications, preclinical evidence, and analytical associations.
Following curation and assignment of levels of evidence, we identified 41 clinically relevant
alterations in 15 out of 16 patients. These included standard-of-care findings, such as an
EGFRL858R mutation in lung adenocarcinoma linked to EGFR inhibitors (predictive for
FDA-approved therapies, Level A), and PIK3CA alterations that are entry criteria for
clinical trials (predictive for therapies in clinical trials, Level A). 46.3% (19/41) of these
alterations were based on preclinical evidence for the association of the alteration with
response or resistance to FDA-approved therapies or therapies in clinical trials (Level D)
(Fig. 4B, Supplementary Table 8).
Multiple unexpected clinically relevant findings were identified in genes not well
characterized for the corresponding tumor type. For instance, CRKL amplification was
observed in a patient with metastatic urothelial carcinoma (Supplementary Fig. 6); this
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talteration has been predicted to confer resistance to EGFR inhibitors26 and sensitivity to Src
inhibitors27 in preclinical studies, but had not previously been described in urothelial
carcinoma. To accommodate new TARGET genes emerging with future findings, we have
made TARGET publically available online and encourage community contributions.
The use of WES in clinical decision-making
The prospective WES framework was used for clinical decision-making in one
demonstrative case. A patient with metastatic lung adenocarcinoma underwent standard
clinical genetic testing that revealed wild-type EGFR, KRAS (codon 12 and 13), and ALK
status. Mass spectrometry testing of 471 alterations in 41 genes5 revealed an STK11
frameshift deletion. The patient was started on carboplatin, paclitaxel, and bevacizumab
(Fig. 5A). In parallel, we applied the clinical WES platform on the FFPE metastatic tumor
sample and germline peripheral blood. PHIAL nominated a KRASA146V mutation, along
with alterations in STK11 (identical to other testing) and ATM (Fig. 5A, Supplementary
Table 8). KRASA146V is a known activating mutation, though possibly less potent than the
codon 12 and 13 mutations28. Although activating KRAS mutations are found in 15–30% of
all patients with non-small cell lung cancer (NSCLC) and commonly in conjunction with
STK11 loss29, this specific KRAS alteration has not been reported in NSCLC20,30–32.
KRAS146V was confirmed using the same FFPE tumor sample in a clinical lab that met
Clinical Laboratory Improvement Amendments (CLIA) standards (Knight Diagnostic
Laboratories, Oregon), and then returned to the patient’s oncologist. After rapidly
progressing on combination chemotherapy (Fig. 5B), the patient was enrolled in a phase I
CDK4 inhibitor (LY2835219) clinical trial based on preclinical data (Level D) implicating a
synthetic lethal relationship between activated KRAS and CDK433. The patient achieved
stable disease (per RECIST 1.1 criteria; 7.9% reduction in tumor volume compared to
baseline) and was on therapy for 16 weeks (Fig. 5B–C). Of note, this represented the
patient’s best and only clinical response to any cancer-directed therapy.
To maximize the potential of clinical WES, we also implemented a procedure to generate
experimental evidence for selected Level E (Inferential Association) alterations. An
exemplary case involved WES from a patient with metastatic castration-resistant prostate
cancer (CRPC) that harbored a JAK3R870W missense mutation (Fig. 5D). Activating
mutations in JAK3 have been described in hematological malignancies34, and JAK3
inhibitors are available clinically, including the FDA-approved agent tofacitinib. JAKR870W
has not been previously identified in cancer, and the function of this mutation is unknown.
The crystal structure of JAK3 demonstrates that the arginine at residue 870 directly
coordinates the phosphate group of the primary activating tyrosine phosphorylation site
(pTyr981)35 (Fig. 5E). This interaction is expected to pull JAK3 into the active
conformation. Indeed, residue 870 is conserved as an arginine or lysine in virtually all JAKs.
Given the functional importance of this residue, we hypothesized that this alteration could,
in principle, be activating. Thus, this alteration was categorized as Level E (Supplementary
Table 8).
We utilized a Ba/F3 system to examine the activity of JAK3R870W as compared to JAK3 WT
and a known activating mutation in JAK3, A572V36. Ba/F3 cells are murine hematopoietic
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tcells dependent of IL-3 for survival. Expression of some oncoproteins substitute for IL-3
signaling, allowing for the growth of Ba/F3 cells in the absence of IL-3. This system has
been used extensively to characterize activating mutants of JAK3 in prior studies36. Ba/F3
cells expressing JAK3R870W did not achieve IL-3 independent growth following complete
IL-3 withdrawal, in contrast to cells expressing a known JAK3 activating mutation
(JAK3A572V) or those growing in the presence of IL-3 (Fig. 5F). This suggested JAK3R870W
is unlikely to be an activating mutation and that JAK3 inhibitors are unlikely to benefit this
patient.
Discussion
This study demonstrates that rapid WES can be applied to FFPE clinical samples, and that
robust WES analysis and interpretation can prospectively inform clinical trial enrollment.
This approach incorporates new algorithms to identify clinically relevant alterations among
numerous somatic events. Furthermore, real-time curation of nominated alterations assigns
levels of evidence to the corresponding clinical actions for that alteration in that tumor type.
In a proof-of-concept application, we identified at least one clinically relevant alteration in
15 of 16 patients, and showed how such findings can lead to clinical trial enrollment and
biological discovery.
Targeted sequencing of clinically relevant gene panels (~100s of genes) have recently
become possible from FFPE tumor samples7, and are increasingly used clinically. However,
there are numerous advantages to clinical WES over targeted sequencing. First, as the
spectrum of clinically actionable alterations grows2, targeted sequencing of particular genes
are likely to be incomplete: the rapid pace of drug development linked to a growing number
of clinically relevant genes will likely outpace the ability to alter targeted sequencing
approaches in real time, just as performing clinical WES becomes more facile and cost-
efficient. The completeness of clinical WES also enables longitudinal queries if new clinical
trials open for previously unrecognized cancer genes not acted on initially.
Furthermore, we expect the volume of inferentially actionable or unknown significance
alterations will rise as more patient exomes emerge clinically. Clinical WES allows the
generation of deeply annotated genomic data (linked to outcomes and responses) that could
be mined to inform TARGET entries. We recognize that the pace of cancer discovery will
necessitate continual TARGET updates to ensure its relevance, and we encourage input from
the clinical and scientific community to expand and update its content for all to benefit.
Methods to aggregate such data in a systems biology approach37 are being developed to
foster functional and clinical follow-up38,39.
There are ways to improve upon the framework. Efforts to further minimize the input DNA
requirement and predict which samples yield successful WES will improve production-level
sequencing. This process will be enhanced by pathology review of clinical samples to enrich
tumor DNA selection. Improvements in exome-derived copy number algorithms will better
distinguish homozygous from heterozygous deletions in stromally admixed tumor samples.
Integration of additional profiling technologies (e.g. transcriptome) will provide increasingly
complex views of an individual patient’s cancer and incorporate other changes (e.g.
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tepigenetic) that may have clinical relevance. In parallel, efforts to demonstrate the utility of
massively parallel sequencing platforms in larger prospective clinical settings are underway.
PHIAL is heuristic-based; a probabilistic model that assesses alteration clonality with
preclinical data may better inform the functional impact of WES findings for individual
patients. Even with predictive models, sequencing will frequently identify novel alterations
in known genes. Furthermore, relevant information about known genomic alterations is
constantly changing, and the availability of novel therapies and clinical trials is in rapid flux.
Because of this, alteration interpretation presently requires real-time manual curation, which
requires dedicated and skilled resources that would benefit from crowdsourcing efforts like
we are establishing with TARGET and PHIAL.
Finally, rapid experimental validation of Level E alterations to understand their clinical
relevance will require innovations of scale to accelerate functional follow-up. Our
experimental efforts described here establish a priority biological evaluation system for one
type of functional assessment. A flexible experimental follow-up system to comprehensively
assess any alteration will need to be developed.
With the “start to finish” approach for clinical WES described here, it is possible to
implement these methods widely and facilitate routine WES in clinical oncology. Once
implemented, this will enable the prospective study of patients in trials to determine if large-
scale genomic profiling improves patient care and, ultimately, outcomes.
ONLINE METHODS
Patient samples
Tumor and germline sample used for this study were obtained under approved protocols
from the Dana-Farber/Harvard Cancer Center Institutional Review Board, the Peter
MacCallum Cancer Center Ethics Committee or the Massachusetts Institute of Technology
Committee on the Use of Humans as Experimental Subjects. Written informed consent was
obtained from all subjects.
Rapid FFPE sequencing
Using industrial best practices in workflow design and a value-add approach, the standard
exome workflow was modified to minimize touch points, handoffs, and wasted process
steps. Second, optimizations were made to the library construction and in-solution
hybridization protocols to enable a 17-hour hybridization reaction, 55 hours shorter than the
standard 72-hour hybridization reaction.
FFPE DNA extraction: Paraffin is removed from FFPE sections and cores using CitriSolv™
(Fisher Scientific) followed by ethanol washes, then tissue is lysed overnight at 56°C.
Samples are then incubated at 90°C to remove DNA crosslinks, and extraction is performed
using Qiagen's QIAamp DNA FFPE Tissue Kit.
Library Construction: This was performed as previously described14 with the following
modifications: initial genomic DNA input into shearing was reduced from 3µg to 10–100ng
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tin 50µL of solution. For adapter ligation, Illumina paired end adapters were replaced with
palindromic forked adapters, purchased from Integrated DNA Technologies, with unique 8
base molecular barcode sequences included in the adapter sequence to facilitate downstream
pooling. With the exception of the palindromic forked adapters, the reagents used for end
repair, A-base addition, adapter ligation, and library enrichment PCR were purchased from
KAPA Biosciences in 96-reaction kits. In addition, during the post-enrichment solid phase
reversible immobilization (SPRI) bead cleanup, elution volume was reduced to 20µL to
maximize library concentration, and a vortexing step was added to maximize the amount of
template eluted from the beads. Any libraries with concentrations below 40ng/µl, as
measured by a PicoGreen assay automated on an Agilent Bravo, were considered failures
and reworked from the start of the protocol.
In-solution hybrid selection: Also performed as previously described14 with the following
modifications to the hybridization reaction: prior to hybridization, any libraries with
concentrations >60ng/µL as determined by PicoGreen were normalized to 60ng/µL, and
8.3µL of library was combined with blocking agent, bait, and hybridization buffer. Any
libraries with concentrations between 50 and 60ng/µL were normalized to 50ng/µL, and
10.3µL of library was combined with blocking agent, bait, and hybridization buffer. Any
libraries with concentrations between 40 and 50ng/µL were normalized to 40ng/µL, and
12.3µL of library was combined with blocking agent, bait, and hybridization buffer.
Regardless of library concentration range, the same volume of blocking agent and bait
previously described14 were used, and hybridization buffer volume was adjusted to equal the
combined volume of library, blocking agent, and bait. Finally, the hybridization reaction
was reduced to 17 hours with no changes to the downstream capture protocol.
Preparation of libraries for cluster amplification and sequencing: After post-capture
enrichment, libraries were quantified using PicoGreen (automated assay on the Agilent
Bravo), normalized to equal concentration on the Perkin Elmer MiniJanus, and pooled by
equal volume on the Agilent Bravo. Library pools were then quantified using quantitative
PCR (kit purchased from KAPA Biosystems) with probes specific to the ends of the
adapters; this assay was automated using Agilent’s Bravo liquid handling platform. Based
on qPCR quantification, libraries were normalized to 2nM, then denatured using 0.2 N
NaOH on the Perkin-Elmer MiniJanus. After denaturation, libraries were diluted to 20pM
using hybridization buffer purchased from Illumina.
Cluster amplification and sequencing: Cluster amplification of denatured templates was
performed according to the manufacturer’s protocol (Illumina) HiSeq v3 cluster chemistry
and flowcells, as well as Illumina’s Multiplexing Sequencing Primer Kit. Flowcells were
sequenced using HiSeq 2000 v3 Sequencing-by-Synthesis Kits, then analyzed using RTA v.
1.12.4.2 or later. Each pool of whole exome libraries was run on paired 76bp runs, and 8
base index sequencing read was performed to read molecular indices, across the number of
lanes needed to meet coverage for all libraries in the pool.
Statistical analysis of raw sequencing metrics: All analyses of raw sequencing metrics were
performed using the R statistical package. Sample size was established by incorporating all
available FFPE samples sequenced under the FFPE sequencing protocol by the time of
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tanalysis freeze (n = 99). Significance between two means (FFPE and non-FFPE samples for
the sequencing metrics) was calculated with the two-tailed Mann-Whitney test given the
non-normal distribution of values. P < 0.05 was considered significant.
Analysis and Interpretation
DNA Assembly and Quality Control—Sequence data processing: Exomes sequence
data processing was performed using established pipelines at the Broad Institute. A BAM
file was produced with the Picard pipeline (http://picard.sourceforge.net/), which aligns the
tumor and normal sequences to the hg19 human genome build using Illumina sequencing
reads. The BAM was uploaded into the Firehose pipeline (http://www.broadinstitute.org/
cancer/cga/Firehose), which manages input and output files to be executed by
GenePattern40. Whole exome sequencing BAM files for data from this study cases will be
deposited in dbGAP (phs000488 for lung adenocarcinoma cases; phs number pending for
clinical cases).
Sequencing quality control: Quality control modules within Firehose were applied to all
sequencing data for comparison of the origin for tumor and normal genotypes and confirm
fingerprinting concordance. Cross-contamination of samples was estimated using ContEst41,
to confirm that neither tumor nor germline sample had > 3% contamination. SNP
fingerprints from each lane of a tumor/normal pair were cross-checked to confirm
concordance, and non-matching lanes were removed from analysis.
Somatic alteration identification and annotation—The MuTect algorithm19 was
applied to identify somatic single-nucleotide variants in targeted exons. Indelocator (http://
www.broadinstitute.org/cancer/cga/indelocator) was applied to identify small insertions or
deletions. Annotation of identified variants was done using Oncotator (http://
www.broadinstitute.org/cancer/cga/oncotator). Rearrangments were identified using
dRanger (http://www.broadinstitute.org/cancer/cga/dranger). Copy ratios were calculated for
each hybrid capture bait by dividing the tumor coverage by the median coverage obtained in
a set of reference normal samples42. The resulting copy ratios were segmented using the
circular binary segmentation algorithm43. Genes in copy ratio regions with segment means
of greater than log2(4) were evaluated for focal amplifications given the potential clinical
significance of a large focal event. Genes in regions with segment means of less than
log2(0.5) were evaluated for hemizygous or homozygous deletions, since either broad or
focal deletions may involve genes with clinical relevance. RefSeq44 was used to identify the
genes that reside in the chromosomal coordinates demarcated by the segment start and end
points.
Cross-validation of FFPE and Fresh Frozen mutation data—FFPE sections were
received as 15µ slices (9 per sample), aged 2007–2009. All FFPE samples were sequenced
as described above with 100ng of input DNA. Frozen tumor samples were sequenced
according to established methods14. All downstream computational analysis methods for
assembly, alignment, mutation, and copy number alteration identification were identical to
the pipelines described above. For the downsampling experiment, MuTect was re-run on all
the cases with the “downsample_to_coverage” parameter set to 90. Mutations in intronic
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tregions were excluded. For cross-validation of mutations, validation power was defined as
the probability to observe at least two alternative allele reads in the validation sample (given
the allelic fraction, coverage in validation sample at that site, and the assumption that the
mutation should be present there).
Statistical analysis of FFPE and frozen tissue: Two-tailed Fisher’s exact test was used to test
the statistical significance of the contingency table represented by tissue type (FFPE or
frozen) and validation status. Pearson correlation was performed on log2(Target Copy Ratio)
segment mean data for FFPE and frozen exon targets and significance was calculated using
Pearson’s product moment correlation coefficient. Sample size for exons from all 11 cases
(n = 1,338,859) greatly exceeded the minimum sample size needed to determine a linear
correlation coefficient of 0.8 with power of 0.8 and significance level of 0.05. The variance
estimate among FFPE (0.054) and frozen (0.049) copy number signal data was similar.
Whole exome sequencing data for lung adenocarcinoma cases will be deposited in dbGAP
(phs000488).
Clinical Gene Database (TARGET)—The TARGET (tumor alterations relevant for
genomics-driven therapy) database included genes that, when altered somatically in cancers,
met one of three criteria:
1. Alterations in the gene predicted resistance and/or sensitivity to specific therapies
2. Alterations in the gene had prognostic significance in a cancer type
3. Alterations in the gene had diagnostic significance in a cancer type.
To build this database, we performed a systematic review of the primary literature, manually
curated specific genes based on clinician input, and consulted expert opinion. This resulted
in a list of 121 genes that met at least one of the three criteria required for entry into the
TARGET database (Supplementary Table 5, available for download at
www.broadinstitute.org/cancer/cga/target).
Somatic heuristic algorithm for interpretation (PHIAL)—Each somatic variant was
scored individually using a series of rules, and then was considered in aggregate to
determine relationships between alterations in the same patient (e.g. linked pathways). First,
variants in TARGET are ranked highest, with scoring modifications for known mutational
hotspots (e.g. BRAF V600E), missense mutations in protein kinase regions, and copy
number alterations with directionality known to have clinical impact (e.g. PTEN deletion).
To assign maximum granularity between alterations, additional rules assign priority based
on presence of recurrent alterations in the Cancer Gene Census45, presence in the pathway
of concurrently altered actionable genes in the same sample using curated cancer pathways
from MSigDB46, presence in known cancer pathways, gene sets, or modules identified by
MSigDB, and finally presence in COSMIC30. All code for PHIAL was implemented using
the R statistical package language and is available online (www.broadinstitute.org/
cancer/cga/phial).
Visual Representation—A decision support tool built around the results was developed
to allow curation team members and clinicians to engage the data with web-based resources
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tintegrated directly into the patient’s results. The tool is built to convey effective clinical
review with the minimum manual steps so that such a process can be scaled rapidly. The
report structure was implemented using the Nozzle R package47. All clinically actionable
relevant somatic variants were linked to search criteria in ClinicalTrials.gov.
Curation—Somatic alterations nominated by PHIAL as “investigate clinical relevance”
were assigned for curation by a team of oncology and genomics experts charged with
answering a series of structured questions pertaining to each nominated variant to facilitate
final review (Supplementary Fig. 6). A curated alteration required review of published data
to determine which level of evidence could be assigned to a clinical action for the alteration
(Table 1).
Clinical Trial Data Analyses—Clinicaltrials.gov (http://clinicaltrials.gov/) was accessed
on 2/19/2013 and the search entry “cancer” was used to extract all cancer-related clinical
trials in the database. Duplicated trial entries and trials designated as “Terminated” or
“Withdrawn” were excluded. Provided trial start dates date (by year) were used to select all
trials that were initiated between 2005 and 2012, and trial titles were queried using string
matching in R for those that specifically mention TARGET genes in the title of the trial.
Ba/F3 Experimental Methods
Cell Culture—HEK293T cells were maintained in DMEM (Gibco) with 10% (vol/vol)
fetal bovine serum (Gibco). Ba/F3 cells (a kind gift of Dr. Andrew Lane at Dana-Farber
Cancer Institute) were maintained in RPMI 1640 (Gibco) with 10% FBS and 10 ng/mL
mouse interleukin-3 (IL-3; Prospec).
Retroviral infections—The wild-type JAK3 cDNA cloned in the pDONR223 vector was
obtained from The Broad Institute RNAi Consortium. JAK3 mutations were generated by
site-directed mutagenesis using the QuikChange Lightning Mutagenesis Kit (Stratagene),
and verified by full sequencing of the JAK3 cDNA insert. WT and mutant cDNAs were
recombined into a Gateway adapted MSCV-puromycin vector (kind gift of Dr. Akinori
Yoda at Dana Farber Cancer Institute) using the Gateway LR Clonase kit. Ecotropic viruses
were produced by cotransfection of MSCV-constructs with pCL-Eco vector (Imgenex) in
293T cells. Ba/F3 cells were plated in 6-well plates at a 30% confluency, and spin infected
at 800 × g for 90 min at 33 °C in the presence of 8 µg/mL polybrene (hexadimethrine
bromide; Sigma). The same infection protocol was repeated 24 h later. Upon completion, the
viral supernatant was removed and fresh media added. Twenty-four hours after the media
change, Ba/F3 cells were subjected to a 3-day puromycin selection (2 µg/mL) in the
presence of IL-3. Expression of ectopic JAK3 protein was verified by immunoblot analysis
using a primary antibody against phospho-JAK3 (Cell Signaling #5031).
IL-3 Depletion—Ba/F3 cells and Ba/F3 cells expressing WT and mutant forms of JAK3
were seeded in 25 cm2 vented-cap flasks at 20,000 cells/ml in a total volume of 5mls in the
absence of IL-3 to select IL-3–independent cells. Cells were grown in the absence of IL-3
over several weeks. In parallel, Ba/F3 cells were maintained in 10ng/ml IL-3 throughout as a
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tpositive control. Cell counts were recorded every 4 days using ViCell counter and split as
needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. FFPE and Frozen sequencing metrics
The percentage of target bases covered at 20X, percent selected bases, and percent of zero
coverage targets in FFPE (n = 99) and non-FFPE tissue (n = 768) (1A–C). Additional
quality control metrics for all 867 cases are available in Supplementary Table 1. No
statistically significant difference between FFPE and non-FFPE tissue is observed in these
three metrics (P > 0.05; two-sided Mann-Whitney test).
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tFigure 2. FFPE and frozen data yield comparable alteration data
FFPE and frozen tissue were extracted from identical tumor samples and analyzed for cross-
validation of mutations where there was sufficient power to detect the mutation in the
validation sample (A). FFPE to frozen and frozen to FFPE validation rates binned by allelic
fractions demonstrate similar validation and false positive rates between the two groups (B–
C). Copy number profiles derived from exomes of the same tumor in either FFPE or frozen
tissue yield comparable results (R2 (Pearson) = 0.89; P < 0.001) (D–E). When comparing
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tthe FFPE and frozen segment means for all exons across 11 patients, the R2 (Pearson) = 0.79
(P < 0.001) (F).
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tFigure 3. PHIAL reveals the “long tail” of clinically relevant events
PHIAL takes as input somatic alterations and uses heuristics to assign clinical and biological
significance to each alteration (A). PHIAL uses the TARGET database, a curated set of
genes that are linked to predictive, prognostic, and/or diagnostic clinical actions when
somatically altered in cancers. (B). PHIAL utilizes additional rules to maximize exome data
for individuals, including knowledge about kinase domains, copy number directionality, and
two-hit pathway events (C). The resulting data is visualized for individual or cohort-level
information with this demonstrative PHIAL “gel”. Each alteration is a point sorted by
PHIAL score (top are of highest clinical relevance), color coded by potential clinical
relevance (red), biological relevance (orange), pathway relevance (yellow), or synonymous
variants (gray) (D). A PHIAL “gel” for 511 patient exomes spanning six different disease
types (n = 258,226 total somatic alterations). The size of the point is proportional to the
number of times a given gene arises at that PHIAL score level. (E). This approach highlights
the “long tail” of potentially clinically relevant alterations in TARGET genes (n = 121) that
may be present in an individual patient but does not occur sufficiently to be labeled a
biological driver across a cohort. The majority of events occur in genes that individually are
altered in less than 2% of the overall cohort (F). New cancer clinical trials with TARGET
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(G).
Allen et al. Page 20
Nat Med. Author manuscript; available in PMC 2014 December 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 4. Clinically relevant findings from individual patients
PHIAL results for 14 patients with a spectrum of malignancies, highlighting nominated
clinically actionable alterations in 13 of 14 patients (A). Using the level of evidence
schematic (Table 1), all nominated alterations for patients in this study were manually
curated and assigned a level of evidence (B, Supplementary Table 7). *Denotes patient
sequencing data that predated the rapid WES protocol.
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tFigure 5. Clinical sequencing informs clinical trial enrollment and experimental discovery
The PHIAL output and treatment course for a patient with metastatic lung adenocarcinoma
is shown, with the integration of clinical WES occurring during the patient’s first-line
therapy allowing subsequent clinical trial enrollment (A). The patient’s time to relapse data
for the three treatment regimens received demonstrate that the best and only clinical
response occurred with the CDK4 inhibitor (B). Radiographic imaging demonstrates a small
reduction in a representative metastatic focus for the patient on the CDK4 inhibitor trial after
two cycles of therapy consistent with stable disease (cm: centimeter; measurement is 1.7 ×
1.5 cm for baseline mass and 1.3 × 1.3 cm for two month interval scan of the same mass).
Per RECIST criteria, overall tumor reduction was 7.9% (C). For another patient, PHIAL
nominated a JAK3 missense mutation (D), and given its location in the kinase domain near
alterations previously defined as activating, was considered to have inferential evidence
(Level E) for being clinically actionable. The crystal structure of JAK3 demonstrates that the
arginine at residue 870 directly coordinates the phosphate group of the primary activating
tyrosine phosphorylation site (E). To better characterize this alteration, experimental follow-
up of this alteration was performed in a Ba/F3 system. Overexpression of the patient’s JAK3
mutation did not suggest an activating phenotype or further consideration of JAK3 inhibitor
clinical trial enrollment (F).
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